MA52545B1 - Anticorps pour radionucléides chélatés - Google Patents

Anticorps pour radionucléides chélatés

Info

Publication number
MA52545B1
MA52545B1 MA52545A MA52545A MA52545B1 MA 52545 B1 MA52545 B1 MA 52545B1 MA 52545 A MA52545 A MA 52545A MA 52545 A MA52545 A MA 52545A MA 52545 B1 MA52545 B1 MA 52545B1
Authority
MA
Morocco
Prior art keywords
antibodies
chelated radionuclides
chelated
radionuclides
invention further
Prior art date
Application number
MA52545A
Other languages
English (en)
Other versions
MA52545A (fr
Inventor
Joerg Moelleken
Pablo Umana
Christian Klein
Guy Georges
Barbara Weiser
Sebastian Fenn
Alexander Haas
Florian LIPSMEIER
Felix BORMANN
Daniela MATSCHEKO
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of MA52545A publication Critical patent/MA52545A/fr
Publication of MA52545B1 publication Critical patent/MA52545B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des anticorps qui se lient spécifiquement à des radionucléides chélatés, y compris des anticorps bispécifiques. L'invention concerne en outre l'utilisation de tels anticorps bispécifiques dans des applications telles que la radioimmunoimagerie et la radioimmunothérapie. L'invention concerne en outre des agents de clarification et des compositions utiles dans de tels procédés. Les radionucléides chélatés peuvent être un chélate DOTAM-plomb (Pb).
MA52545A 2018-04-16 2019-04-16 Anticorps pour radionucléides chélatés MA52545B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658468P 2018-04-16 2018-04-16
EP19723014.7A EP3781200B1 (fr) 2018-04-16 2019-04-16 Anticorps pour radionucléides chélatés
PCT/EP2019/059856 WO2019201959A1 (fr) 2018-04-16 2019-04-16 Anticorps pour radionucléides chélatés

Publications (2)

Publication Number Publication Date
MA52545A MA52545A (fr) 2021-02-24
MA52545B1 true MA52545B1 (fr) 2024-08-30

Family

ID=66476592

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52545A MA52545B1 (fr) 2018-04-16 2019-04-16 Anticorps pour radionucléides chélatés

Country Status (31)

Country Link
US (2) US20220389116A1 (fr)
EP (2) EP4406607A3 (fr)
JP (3) JP7475283B2 (fr)
KR (1) KR102884852B1 (fr)
CN (1) CN112261952A (fr)
AR (1) AR115053A1 (fr)
AU (1) AU2019254537B2 (fr)
BR (1) BR112020021061A2 (fr)
CA (1) CA3096338A1 (fr)
CL (1) CL2020002680A1 (fr)
CR (1) CR20200548A (fr)
DK (1) DK3781200T3 (fr)
ES (1) ES2985352T3 (fr)
FI (1) FI3781200T3 (fr)
HR (1) HRP20241013T1 (fr)
HU (1) HUE067622T2 (fr)
IL (1) IL277575B2 (fr)
LT (1) LT3781200T (fr)
MA (1) MA52545B1 (fr)
MX (1) MX2020010954A (fr)
MY (1) MY207044A (fr)
PE (1) PE20210442A1 (fr)
PL (1) PL3781200T3 (fr)
PT (1) PT3781200T (fr)
RS (1) RS65753B1 (fr)
SG (1) SG11202010066TA (fr)
SI (1) SI3781200T1 (fr)
TW (1) TWI874314B (fr)
UA (1) UA130541C2 (fr)
WO (1) WO2019201959A1 (fr)
ZA (1) ZA202006121B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
AR119382A1 (es) * 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
WO2022008688A1 (fr) * 2020-07-10 2022-01-13 F. Hoffmann-La Roche Ag Anticorps se liant à des cellules cancéreuses et ciblant ces cellules avec des radionucléides
PE20240690A1 (es) 2021-01-12 2024-04-10 Hoffmann La Roche Anticuerpos split que se unen a celulas cancerosas y dirigen radionuclidos a dichas celulas
CN116744981A (zh) * 2021-01-13 2023-09-12 豪夫迈·罗氏有限公司 组合疗法
AU2022207624A1 (en) * 2021-01-13 2023-07-13 F. Hoffmann-La Roche Ag Combination therapy
JP2024546810A (ja) 2021-12-15 2024-12-26 ワイ－マブス セラピューティクス， インコーポレイテッド 多量体化が低減されているｓｃＦｖ及び抗体
WO2024099526A1 (fr) 2022-11-08 2024-05-16 Y-Mabs Therapeutics, Inc. Composés d'anticorps bispécifiques
IL330142A (en) 2024-02-20 2026-08-01 F Hoffmann La Roche Ag New Antibodies for Pre-Targeting and Their Uses
WO2026041568A1 (fr) 2024-08-20 2026-02-26 F. Hoffmann-La Roche Ag Anticorps se liant à cd3 et dotam
WO2026082710A1 (fr) 2024-10-16 2026-04-23 F. Hoffmann-La Roche Ag Récepteurs recombinants inductibles par de petites molécules

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2943299A1 (fr) * 2014-04-11 2015-10-15 Medimmune, Llc Anticorps anti-her2 bispecifiques
WO2016102536A1 (fr) * 2014-12-23 2016-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques destinés au traitement de surinfections bactériennes post-grippales
WO2016126950A1 (fr) * 2015-02-05 2016-08-11 Molecular Templates, Inc. Molécules multivalentes de liaison à cd20 comprenant des régions effectrices de sous-unité a de la toxine shiga et compositions enrichies correspondantes
WO2016130539A2 (fr) * 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Anticorps multi-spécifiques ayant une affinité pour l'antigène a33 humain et le complexe métallique dota et utilisations de ceux-ci
JP7044700B2 (ja) * 2015-10-02 2022-03-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子
EP3243836A1 (fr) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG Molécules de liaison à un antigène contenant un trimère d'un ligand de la famille du tnf fusionné en terminaison c
PL3781201T3 (pl) * 2018-04-16 2026-02-23 Orano Med Manufacturing SAS Przeciwciała dla chelatowanych radionuklidów i środków klarujących

Also Published As

Publication number Publication date
MX2020010954A (es) 2020-11-09
CA3096338A1 (fr) 2019-10-24
CN112261952A (zh) 2021-01-22
EP4406607A2 (fr) 2024-07-31
CL2020002680A1 (es) 2021-02-12
IL277575A (en) 2020-11-30
KR20210005885A (ko) 2021-01-15
PL3781200T3 (pl) 2024-09-16
KR102884852B1 (ko) 2025-11-14
EP3781200A1 (fr) 2021-02-24
UA130541C2 (uk) 2026-03-18
MY207044A (en) 2025-01-27
EP4406607A3 (fr) 2024-10-16
JP2021520832A (ja) 2021-08-26
PT3781200T (pt) 2024-07-19
IL277575B2 (en) 2025-11-01
SG11202010066TA (en) 2020-11-27
EP3781200B1 (fr) 2024-05-29
HUE067622T2 (hu) 2024-10-28
AU2019254537B2 (en) 2025-06-19
US20260015436A1 (en) 2026-01-15
BR112020021061A2 (pt) 2021-02-17
RS65753B1 (sr) 2024-08-30
US20220389116A1 (en) 2022-12-08
JP2024056687A (ja) 2024-04-23
AR115053A1 (es) 2020-11-25
DK3781200T3 (da) 2024-08-05
ES2985352T3 (es) 2024-11-05
FI3781200T3 (fi) 2024-07-31
TWI874314B (zh) 2025-03-01
LT3781200T (lt) 2024-08-12
CR20200548A (es) 2021-01-20
JP2026062683A (ja) 2026-04-10
WO2019201959A1 (fr) 2019-10-24
HRP20241013T1 (hr) 2024-10-25
ZA202006121B (en) 2025-05-28
MA52545A (fr) 2021-02-24
IL277575B1 (en) 2025-07-01
TW202011987A (zh) 2020-04-01
AU2019254537A1 (en) 2020-10-29
JP7475283B2 (ja) 2024-04-26
PE20210442A1 (es) 2021-03-08
SI3781200T1 (sl) 2024-09-30

Similar Documents

Publication Publication Date Title
ZA202006121B (en) Antibodies for chelated radionuclides
MA29243B1 (fr) Agonistes de pyy et leurs utilisations
MA58293B1 (fr) Molécules de liaison pd-1 et leurs procédés d'utilisation
MA39313A1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
MA30047B1 (fr) Procede destine a traiter une lesion articulaire
MA34753B1 (fr) Compositions et procédés de traitement dans des applications cliniques à large spectre, indifférenciées ou mixtes
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
CY1110337T1 (el) Παρασκευη πρεγκαμπαλινης και σχετικων ενωσεων
MA30470B1 (fr) Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste.
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA42439B1 (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
WO2018220060A3 (fr) Raccords d'instrument et procédés associés
MA44909A (fr) Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
MA30159B1 (fr) Agents de durcissement pour composes a fonctions epoxy
PL1886140T3 (pl) Testy immunologiczne i przeciwciała wobec hormonu anty-Müllerowskiego
MA30331B1 (fr) ANTICORPS à EFGL 7 ET LEURS PROCEDES D'UTILISATION
EP4337268A4 (fr) Procédés et compositions pour l'intégration génomique
MX2021015156A (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
MA30889B1 (fr) Inhibiteurs de la kinase mapk/erk
MA37317A1 (fr) Formulation d'anticorps il-17
EP4162054A4 (fr) Compositions et procédés pour l'édition de l'épigénome
MA38342B1 (fr) Composition de revêtement durcissable oxydativement
FR3082427B1 (fr) Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
MA20150357A1 (fr) Procédés de réduction de la formation de tartre